Transformed follicular lymphoma (tFL): consolidation therapy may improve survival

Transformed follicular lymphoma (tFL): consolidation therapy may improve survival Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identified from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Irish Journal of Medical Science (1971 -) Springer Journals

Transformed follicular lymphoma (tFL): consolidation therapy may improve survival

Loading next page...
 
/lp/springer_journal/transformed-follicular-lymphoma-tfl-consolidation-therapy-may-improve-AtbZyRA45U
Publisher
Springer London
Copyright
Copyright © 2017 by Royal Academy of Medicine in Ireland
Subject
Medicine & Public Health; Internal Medicine; General Practice / Family Medicine
ISSN
0021-1265
eISSN
1863-4362
D.O.I.
10.1007/s11845-017-1594-z
Publisher site
See Article on Publisher Site

Abstract

Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identified from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had

Journal

Irish Journal of Medical Science (1971 -)Springer Journals

Published: Mar 21, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off